Merck recognizes that new methods and a broader scope of partnering—with both public and private entities—are critical to continuing innovation. This is true for all diseases, and especially true for neglected diseases, for which the relevant expertise spans academia, a diverse set of local public health authorities, industry and international agencies. We plan to continue to expand our interaction with these groups in order to understand key research priorities and opportunities, and to support those with relevant expertise and resources where possible, including for developing world diseases.